SPL7013 ophthalmic drops potential, page-9

For those new to forum.....I believe DG is referring to George Holan

The company, Starpharma Pdf, was formed in 1994 by the BRI’s Manager Dr John Raff, based on the dendrimer work and a set of antiviral and angiogenesis inhibition (anti-cancer) patents. The patents, projects and discoveries of George Holan, in the dendrimer and polyoxometalate field were transferred to this company which continued operating research after the disbandment of BRI on 31 December 2000.

From 1998 to 2002, Holan designed anionic dendrimers which were synthesised by Dr B Matthews and were the basis of eight patents that formed the intellectual property establishing the company Starpharma Pdf, later ASX listed company Starpharma Ltd. Based on his discoveries, Dr Holan obtained for Starpharma, in 1998, a Commonwealth Start Grant that partially financed the initial drug development. One of three patented dendrimers (GH7013, later SPL7013) was tested originally for antiviral HIV properties at REGA Medical Research Institute of the Catholic University, in Leuven, Belgium. Later cell tests confirmed its activity also against Herpes viruses 1 and 2 at the University of Alabama, Birmingham AL and in animals at Cincinnati Medical Centre (NIAID).

This compound became the active ingredient of a candidate prophylactic microbicide for STDs. The formulated agent known as Viva Gel was tested and passed later in several clinical tests as a safe agent for potential use as HIV and Herpes infection preventative microbicide